Evidence map›Paper›PMID 33280417›Full record

ArticleDiabetes & vascular disease research

Epigallocatechin-3-gallate ameliorates glucolipid metabolism and oxidative stress in type 2 diabetic rats.

Wenru Li, Chaonan Zhu, Tianheng Liu, Weifang Zhang, Xu Liu, Peng Li, Tiantian Zhu

Open access · diamondAbstract read
In one paragraph

Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Vitamin D Alleviates Type 2 Diabetes Mellitus by Mitigating Oxidative Stress-Induced Pancreatic β-Cell Impairment.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Frontiers in pharmacology · 2021
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenru LiCollege of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, China.
Chaonan ZhuCollege of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, China.
Tianheng LiuCollege of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, China.
Weifang ZhangDepartment of Pharmacy, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Xu LiuCollege of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, China.
Peng LiCollege of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, China.
Tiantian ZhuCollege of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, China.ORCID 0000-0001-9017-6680
Xinxiang Medical University · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe objective of this study was to explore the effects of epigallocatechin-3-gallate (EGCG) on type 2 diabetes mellitus (T2DM). MAIN

methodsMale Sprague-Dawley rats were allocated into six groups. The control group received a conventional diet. The diabetic group received a high-sucrose high-fat (HSHF) diet for 4 weeks and then was fasted and injected with streptozotocin (STZ); subsequently, the rats received a HSHF diet for another 4 weeks to develop diabetes. The four treatment groups were diabetic rats that received intragastric metformin (500 mg/kg/day) or EGCG (25, 50, and 100 mg/kg/day) for 10 weeks. All groups except the control group received a HSHF diet throughout the experiment. Several biochemical parameters such as fasting blood glucose (FBG), postprandial blood glucose (PBG), liver glycogen, muscle glycogen, fasting serum insulin (FSI), homeostasis model of insulin resistance (HOMA-IR), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), free fatty acids (FFA), superoxide dismutase (SOD), and malondialdehyde (MDA) were measured to assess the effects of EGCG on glycemic control, insulin resistance, lipid profile, and oxidative stress. Furthermore, oxidative stress in pancreatic islet β cells was detected by dihydroethidium staining. KEY

findingsA HSHF diet and STZ injection induced T2DM, as indicated by changed blood glucose and body weight, which was accompanied by insulin resistance, an altered lipid profile, and oxidative stress. Interestingly, EGCG treatment dose-dependently recovered these indexes. SIGNIFICANCE: EGCG successfully ameliorated glycemic control and insulin sensitivity while reducing the lipid profile and oxidative stress in a T2DM rat model.

Indexed as

AnimalsAntioxidantsBiomarkersBlood GlucoseCatechinDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Dietary SucroseDiet, High-FatHypoglycemic AgentsHypolipidemic AgentsInsulin ResistanceInsulin-Secreting CellsLipidsLiverMaleAntioxidantsBiomarkersBlood GlucoseCatechinDietary Sucroseepigallocatechin gallateHypoglycemic AgentsHypolipidemic AgentsLipidsStreptozocinEpigallocatechin-3-gallateglycemic controlinsulin resistancelipid profileoxidative stresstype 2 diabetes mellitus

Identifiers

PMID33280417
PMCPMC7919214
OpenAlexW3112538946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.